Regeneron Reports First Quarter 2019 Financial and Operating Results

Tuesday, May 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

TABLE 5

REGENERON PHARMACEUTICALS, INC.

NET PRODUCT SALES OF REGENERON-DISCOVERED PRODUCTS (Unaudited)

(In millions)

Three Months Ended March 31,

2019

2018

U.S.

ROW

Total

U.S.

ROW

Total

EYLEA*

$

1,074.1

$

669.4

$

1,743.5

$

984.0

$

624.0

$

1,608.0

Libtayo

26.8

26.8

ARCALYST

3.5

3.5

3.9

3.9

Net product sales recorded by    Regeneron

$

1,104.4

$

987.9

Net product sales recorded by Sanofi*:

Dupixent

$

303.0

$

70.7

$

373.7

$

116.8

$

14.6

$

131.4

Praluent

$

22.9

$

41.0

$

63.9

$

31.7

$

28.2

$

59.9

Kevzara

$

20.7

$

13.0

$

33.7

$

9.3

$

3.1

$

12.4

ZALTRAP

$

0.5

$

24.0

$

24.5

$

2.4

$

23.9

$

26.3

* Bayer records net product sales of EYLEA outside the United States and Sanofi records global net product sales of Dupixent, Praluent, Kevzara, and ZALTRAP.  Refer to Table 4 for the Company's share of profits/losses recorded in connection with sales of EYLEA outside the United States and global sales of Dupixent, Praluent, and Kevzara.  Sanofi pays the Company a percentage of aggregate net sales of ZALTRAP.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store